Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Form 8.3 - Evolution Group plc

16 Sep 2011 12:37

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, on

dealings are being disclosed: behalf of discretionary clients.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is

insufficient

(c) Name of offeror/offeree in relation to Evolution Group plc whose relevant securities this form relates: Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify

identity of offeror/offeree:

(e) Date position held/dealing undertaken: 15 September 2011 (f) Has the discloser previously disclosed, or NO are they today disclosing, under the Code in respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number % (1) Relevant securities owned 26,778,535 11.51 0 0.0 and/or controlled: (2) Derivatives (other than options): (3) Options and agreements to purchase/sell: TOTAL: 26,778,535 11.51 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in N/A relation to which subscription right

exists:

Details, including nature of the N/A

rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 753,497 92p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price

date money security e.g. call selling, to which per unit e.g.

paid/

option varying option American, received etc. relates European per unit etc. N/A (ii) Exercising

Class of relevant Product Number of Exercise price

per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or

understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person

making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none" None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal,

between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant

securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Aberforth Partners LLP ("Aberforth") provided a non-binding letter of intent to Investec plc regarding Investec's plc's proposed acquisition of Evolution Group plc ("Evolution"), as referred to in the announcement of the Recommended Share Offer dated 9 September 2011. On 15 September 2011,

Aberforth disposed of 464,300 shares (over which it had voting authority) in Evolution, on behalf of clients. As a result, Aberforth now intends to vote

in favour of the resolutions to be proposed at the Court Meeting and the Evolution general meeting necessary to approve the Scheme (or as the case maybe, to accept the Takeover Offer) in respect of 15,333,344 Evolution shares, over which it has voting authority.

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 16 September 2011 Contact name: David Holland, for Aberforth Partners LLP Telephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

XLON
Date   Source Headline
22nd Mar 20217:00 amRNSAppointment of Chief Business Officer
15th Mar 20219:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSUpdate on Data Safety Review - STAR COVID-19 trial
9th Mar 202111:35 amRNSHolding(s) in Company
8th Mar 20211:49 pmRNSHolding(s) in Company
5th Mar 20214:04 pmRNSHolding(s) in Company
5th Mar 20219:17 amRNSDirector dealing
3rd Mar 202112:10 pmRNSResult of General Meeting & Total Voting Rights
3rd Mar 20217:00 amRNSResult of Open Offer
26th Feb 20214:39 pmRNSHolding(s) in Company
17th Feb 20219:58 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSUpdate on patient recruitment
12th Feb 20217:00 amRNSPosting of Circular & Notice of GM
2nd Feb 20213:15 pmRNSPlacing and Open Offer to raise up to £11 million
22nd Jan 20217:00 amRNSPreclinical data on a new therapeutic target
21st Jan 20217:00 amRNSPositive pre-clinical data for lead asset SFX-01
19th Jan 20217:00 amRNSPatient recruitment update in STAR-COVID 19 trial
23rd Dec 20202:05 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:00 pmRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSHalf-year Report
27th Nov 20202:33 pmRNSHolding(s) in Company
27th Nov 20209:15 amRNSHolding(s) in Company
23rd Nov 20207:00 amRNSRecruitment of first patient in STAR trial
11th Nov 20207:00 amRNSComment on the COVID-19 vaccine announcement
6th Nov 20209:25 amRNSHolding(s) in Company
29th Oct 202011:55 amRNSHolding(s) in Company
29th Oct 20209:09 amRNSHolding(s) in Company
26th Oct 20203:00 pmRNSHolding(s) in Company
23rd Oct 20207:00 amRNSAll approvals received for STAR trial to commence
6th Oct 20207:00 amRNSGrant of options
24th Sep 20207:00 amRNSAppointment of Chief Executive Officer
15th Sep 20207:00 amRNSLicence agreement with Juvenescence
18th Aug 20203:30 pmRNSHolding(s) in Company
18th Aug 20203:25 pmRNSHolding(s) in Company
14th Aug 20204:41 pmRNSSecond Price Monitoring Extn
14th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
31st Jul 20203:40 pmRNSHolding(s) in Company
24th Jul 20209:47 amRNSShare option exercise and issue of equity
17th Jul 202012:05 pmRNSHolding(s) in Company
17th Jul 202012:02 pmRNSHolding(s) in Company
16th Jul 20202:52 pmRNSResult of AGM
7th Jul 202011:13 amRNSShare option exercise and issue of equity
6th Jul 20207:00 amRNSShare option exercise and issue of equity
23rd Jun 202011:44 amRNSHolding(s) in Company
23rd Jun 202011:38 amRNSHolding(s) in Company
19th Jun 20207:00 amRNSNotice of AGM
17th Jun 20209:38 amRNSHolding(s) in Company
17th Jun 20209:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.